Cargando…

ODP236 Reducing length of Hospital Stay and Mortality in COVID-19 Patients with Diabetes

INTRODUCTION: & BACKGROUND: Diabetes in COVID-19 patients is individual risk factor and documented in worldwide studies to contribute to disease severity, increased length of stay and higher mortality (fig-1). Aggressive management of blood sugars and acute diabetic complications reduce the leng...

Descripción completa

Detalles Bibliográficos
Autores principales: Bokhari, Samia, Khan, Patan, Shareef, Muneera A, Safwat, Rania, Galal, Mohamed, Qadi, Hamdi, Alzahrani, Ameerah, Boraie, Rehab A, Zahrani, Sara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624690/
http://dx.doi.org/10.1210/jendso/bvac150.686
_version_ 1784822295706992640
author Bokhari, Samia
Khan, Patan
Shareef, Muneera A
Safwat, Rania
Galal, Mohamed
Qadi, Hamdi
Alzahrani, Ameerah
Boraie, Rehab A
Zahrani, Sara
author_facet Bokhari, Samia
Khan, Patan
Shareef, Muneera A
Safwat, Rania
Galal, Mohamed
Qadi, Hamdi
Alzahrani, Ameerah
Boraie, Rehab A
Zahrani, Sara
author_sort Bokhari, Samia
collection PubMed
description INTRODUCTION: & BACKGROUND: Diabetes in COVID-19 patients is individual risk factor and documented in worldwide studies to contribute to disease severity, increased length of stay and higher mortality (fig-1). Aggressive management of blood sugars and acute diabetic complications reduce the length of stay and mortality. METHODS: Randomly selected 200 patients admitted with diabetes and COVID-19 studied. The unified treatment protocol (fig-2) applied for all patients and blood sugars monitored closely and optimized. Data collected on bimonthly basis and analyzed. Patients’ characteristics taken from data extraction tool (Oasis) of hospital. Median values for length of stay and post discharge FBS and RBS were calculated Microsoft Excel tool. Mortality rates calculated by percentages. RESULTS: 200 patients studied in the 4 months study period. The median length of stay was 3 days. The mortality rate was 2.5% (fig-3,4). The median FBS and RBS in the patient group monitored in the post discharge clinic was 130 mg/dl and 170 mg/dl respectively. The results compared with the standard international studies. DISCUSSION: Diabetes in COVID-19 patients posed great challenge as increased severity and mortalities reported compared to non-diabetic. Taking a pre-emptive strategy to combat this problem by aggressively manage diabetes help in reducing length of stay and morbidity. The length of stay in studded population was 3 days as compared to 13 days in a major international study(Ref: 1) . Financial saving come from rapid turnover of beds. The mortality was 2.5% compared to reported 7.3% in a major study (Ref: 2), reflecting the implications of aggressive management of diabetes. Regular follow-up and support by running post-discharge clinic definitely help reducing readmissions and acute complications of uncontrolled diabetes. CONCLUSION: Aggressive management of diabetes in COVID-19 patients by tailored treatment protocols and dedicated teams will help to decrease the morbidity and mortality. Presentation: No date and time listed
format Online
Article
Text
id pubmed-9624690
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-96246902022-11-14 ODP236 Reducing length of Hospital Stay and Mortality in COVID-19 Patients with Diabetes Bokhari, Samia Khan, Patan Shareef, Muneera A Safwat, Rania Galal, Mohamed Qadi, Hamdi Alzahrani, Ameerah Boraie, Rehab A Zahrani, Sara J Endocr Soc Diabetes & Glucose Metabolism INTRODUCTION: & BACKGROUND: Diabetes in COVID-19 patients is individual risk factor and documented in worldwide studies to contribute to disease severity, increased length of stay and higher mortality (fig-1). Aggressive management of blood sugars and acute diabetic complications reduce the length of stay and mortality. METHODS: Randomly selected 200 patients admitted with diabetes and COVID-19 studied. The unified treatment protocol (fig-2) applied for all patients and blood sugars monitored closely and optimized. Data collected on bimonthly basis and analyzed. Patients’ characteristics taken from data extraction tool (Oasis) of hospital. Median values for length of stay and post discharge FBS and RBS were calculated Microsoft Excel tool. Mortality rates calculated by percentages. RESULTS: 200 patients studied in the 4 months study period. The median length of stay was 3 days. The mortality rate was 2.5% (fig-3,4). The median FBS and RBS in the patient group monitored in the post discharge clinic was 130 mg/dl and 170 mg/dl respectively. The results compared with the standard international studies. DISCUSSION: Diabetes in COVID-19 patients posed great challenge as increased severity and mortalities reported compared to non-diabetic. Taking a pre-emptive strategy to combat this problem by aggressively manage diabetes help in reducing length of stay and morbidity. The length of stay in studded population was 3 days as compared to 13 days in a major international study(Ref: 1) . Financial saving come from rapid turnover of beds. The mortality was 2.5% compared to reported 7.3% in a major study (Ref: 2), reflecting the implications of aggressive management of diabetes. Regular follow-up and support by running post-discharge clinic definitely help reducing readmissions and acute complications of uncontrolled diabetes. CONCLUSION: Aggressive management of diabetes in COVID-19 patients by tailored treatment protocols and dedicated teams will help to decrease the morbidity and mortality. Presentation: No date and time listed Oxford University Press 2022-11-01 /pmc/articles/PMC9624690/ http://dx.doi.org/10.1210/jendso/bvac150.686 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Diabetes & Glucose Metabolism
Bokhari, Samia
Khan, Patan
Shareef, Muneera A
Safwat, Rania
Galal, Mohamed
Qadi, Hamdi
Alzahrani, Ameerah
Boraie, Rehab A
Zahrani, Sara
ODP236 Reducing length of Hospital Stay and Mortality in COVID-19 Patients with Diabetes
title ODP236 Reducing length of Hospital Stay and Mortality in COVID-19 Patients with Diabetes
title_full ODP236 Reducing length of Hospital Stay and Mortality in COVID-19 Patients with Diabetes
title_fullStr ODP236 Reducing length of Hospital Stay and Mortality in COVID-19 Patients with Diabetes
title_full_unstemmed ODP236 Reducing length of Hospital Stay and Mortality in COVID-19 Patients with Diabetes
title_short ODP236 Reducing length of Hospital Stay and Mortality in COVID-19 Patients with Diabetes
title_sort odp236 reducing length of hospital stay and mortality in covid-19 patients with diabetes
topic Diabetes & Glucose Metabolism
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624690/
http://dx.doi.org/10.1210/jendso/bvac150.686
work_keys_str_mv AT bokharisamia odp236reducinglengthofhospitalstayandmortalityincovid19patientswithdiabetes
AT khanpatan odp236reducinglengthofhospitalstayandmortalityincovid19patientswithdiabetes
AT shareefmuneeraa odp236reducinglengthofhospitalstayandmortalityincovid19patientswithdiabetes
AT safwatrania odp236reducinglengthofhospitalstayandmortalityincovid19patientswithdiabetes
AT galalmohamed odp236reducinglengthofhospitalstayandmortalityincovid19patientswithdiabetes
AT qadihamdi odp236reducinglengthofhospitalstayandmortalityincovid19patientswithdiabetes
AT alzahraniameerah odp236reducinglengthofhospitalstayandmortalityincovid19patientswithdiabetes
AT boraierehaba odp236reducinglengthofhospitalstayandmortalityincovid19patientswithdiabetes
AT zahranisara odp236reducinglengthofhospitalstayandmortalityincovid19patientswithdiabetes